期刊文献+

Synchronous colorectal cancer: Clinical, pathological and molecular implications 被引量:23

Synchronous colorectal cancer: Clinical, pathological and molecular implications
下载PDF
导出
摘要 Synchronous colorectal carcinoma refers to more than one primary colorectal carcinoma detected in a single patient at initial presentation. A literature review has shown that the prevalence of the disease is approximately 3.5% of all colorectal carcinomas. This disease has a male to female ratio of 1.8:1. The mean age at presentation of patients with synchronous colorectal cancer is in the early half of the seventh decade. Patients with inflammatory bowel diseases (ulcerative colitis and Crohn’s disease), hereditary non-polyposis colorectal cancer, familial adenomatous polyposis and serrated polyps/hyperplastic polyposis are known to have a higher risk of synchronous colorectal carcinoma. These predisposing factors account for slightly more than 10% of synchronous colorectal carcinomas. Synchronous colorectal carcinoma is more common in the right colon when compared to solitary colorectal cancer. On pathological examination, some synchronous colorectal carcinomas are mucinous adenocarcinomas. They are usually associated with adenomas and metachronous colorectal carcinomas. Most of the patients with synchronous colorectal cancer have two carcinomas but up to six have been reported in one patient. Patients with synchronous colorectal carcinoma have a higher proportion of microsatellite instability cancer than patients with a solitary colorectal carcinoma. Also, limited data have revealed that in many synchronous colorectal carcinomas, carcinomas in the same patient have different patterns of microsatellite instability status, p53 mutation and K-ras mutation. Overall, the prognosis of patients with synchronous colorectal carcinoma is not significantly different from that in patients with solitary colorectal carcinoma, although a marginally better prognosis has been reported in patients with synchronous colorectal carcinoma in some series. A different management approach and long-term clinical follow-up are recommended for some patients with synchronous colorectal cancer. Synchronous colorectal carcinoma refers to more than one primary colorectal carcinoma detected in a single patient at initial presentation.A literature review has shown that the prevalence of the disease is approximately 3.5%of all colorectal carcinomas.This disease has a male to female ratio of 1.8:1.The mean age at presentation of patients with synchronous colorectal cancer is in the early half of the seventh decade.Patients with inflammatory bowel diseases(ulcerative colitis and Crohn’s disease),hereditary non-polyposis colorectal cancer,familial adenomatous polyposis and serrated polyps/hyperplastic polyposis are known to have a higher risk of synchronous colorectal carcinoma.These predisposing factors account for slightly more than 10%of synchronous colorectal carcinomas.Synchronous colorectal carcinoma is more common in the right colon when compared to solitary colorectal cancer.On pathological examination,some synchronous colorectal carcinomas are mucinous adenocarcinomas.They are usually associated with adenomas and metachronous colorectal carcinomas.Most of the patients with synchronous colorectal cancer have two carcinomas but up to six have been reported in one patient.Patients with synchronous colorectal carcinoma havea higher proportion of microsatellite instability cancer than patients with a solitary colorectal carcinoma.Also,limited data have revealed that in many synchronous colorectal carcinomas,carcinomas in the same patient have different patterns of microsatellite instability status,p53 mutation and K-ras mutation.Overall,the prognosis of patients with synchronous colorectal carcinoma is not significantly different from that in patients with solitary colorectal carcinoma,although a marginally better prognosis has been reported in patients with synchronous colorectal carcinoma in some series.A different management approach and long-term clinical follow-up are recommended for some patients with synchronous colorectal cancer.
出处 《World Journal of Gastroenterology》 SCIE CAS 2014年第22期6815-6820,共6页 世界胃肠病学杂志(英文版)
关键词 Synchronous carcinoma Colorectal carcinoma PREVALENCE Microsatellite instability Review Synchronous carcinoma Colorectal carci-noma Preval
  • 相关文献

参考文献12

  • 1Jessica Weekes,Alfred King-Yin Lam,Sabe Sebesan,Yik-Hong Ho.Irinotecan therapy and molecular targets in colorectal cancer: A systemic review[J].World Journal of Gastroenterology,2009,15(29):3597-3602. 被引量:10
  • 2Hong-ZhiWang Xin-FuHuang Yiwang Jia-FuJi JinGu.Clinical features,diagnosis,treatment and prognosis of multiple primary colorectal carcinoma[J].World Journal of Gastroenterology,2004,10(14):2136-2139. 被引量:44
  • 3Mahin Mohammadi,Michael Holmsgaard Kristensen,Hans J?rgen Nielsen,Jesper Hansen Bonde,Susanne Holck.Qualities of sessile serrated adenoma/polyp/lesion and its borderline variant in the context of synchronous colorectal carcinoma[J].Journal of Clinical Pathology.2012(10)
  • 4Xiuli Liu,John R. Goldblum,Zijin Zhao,Michael Landau,Brandie Heald,Rish Pai,Jingmei Lin.Distinct Clinicohistologic Features of Inflammatory Bowel Disease-associated Colorectal Adenocarcinoma: In Comparison With Sporadic Microsatellite-stable and Lynch Syndrome-related Colorectal Adenocarcinoma[J].The American Journal of Surgical Pathology.2012(8)
  • 5Alfred Lam,Vinod Gopalan,Robert Carmichael,Petra Buettner,Melissa Leung,Robert Smith,Cu-Tai Lu,Yik-Hong Ho,Simon Siu.Metachronous carcinomas in colorectum and its clinicopathological significance[J].International Journal of Colorectal Disease.2012(10)
  • 6Sanna A. Mulder,Ries Kranse,Ronald A. Damhuis,Johannes H.W. de Wilt,Rob J.Th. Ouwendijk,Ernst J. Kuipers,Monique E. van Leerdam.Prevalence and prognosis of synchronous colorectal cancer: A Dutch population-based study[J].Cancer Epidemiology.2011(5)
  • 7Alfred King-Yin Lam,Robert Carmichael,Petra Gertraud Buettner,Vinod Gopalan,Yik-Hong Ho,Simon Siu.Clinicopathological significance of synchronous carcinoma in colorectal cancer[J].The American Journal of Surgery.2011(1)
  • 8Ravi P. Kiran,Wisam Khoury,James M. Church,Ian C. Lavery,Victor W. Fazio,Feza H. Remzi.Colorectal Cancer Complicating Inflammatory Bowel Disease: Similarities and Differences Between Crohn?s and Ulcerative Colitis Based on Three Decades of Experience[J].Annals of Surgery.2010(2)
  • 9Giuliano Di Pietro,Luiz Alexandre V Magno,Fabrício Rios-Santos.Glutathione S-transferases: an overview in cancer research[J].Expert Opinion on Drug Metabolism & Toxicology.2010(2)
  • 10Katsuhiko Nosho,Shoko Kure,Natsumi Irahara,Kaori Shima,Yoshifumi Baba,Donna Spiegelman,Jeffrey A. Meyerhardt,Edward L. Giovannucci,Charles S. Fuchs,Shuji Ogino.A Prospective Cohort Study Shows Unique Epigenetic, Genetic, and Prognostic Features of Synchronous Colorectal Cancers[J].Gastroenterology.2009(5)

二级参考文献66

  • 1Stewart BW,Kleihues P,eds.World Cancer Report.IARC non-serial publication.Lyon:IARC,2003.
  • 2Washington MK.Colorectal carcinoma:selected issues in pathologic examination and staging and determination of prognostic factors.Arch Pathol Lab Med 2008; 132:1600-1607.
  • 3Midgley RS,Yanagisawa Y,Kerr DJ.Evolution of nonsurgical therapy for colorectal cancer.Nat Clin Pract Gastroenterol Hepatol 2009; 6:108-120.
  • 4Glimelius B.Benefit-risk assessment of irinotecan in advanced colorectal cancer.Drug Saf 2005; 28:417-433.
  • 5Cunningham D,Pyrh.nen S,James RD,Punt CJ,Hickish TF,Heikkila R,Johannesen TB,Starkhammar H,Topham CA,Awad L,Jacques C,Herait P.Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.Lancet 1998; 352:1413-1418.
  • 6Rougier P,Van Cutsem E,Bajetta E,Niederle N,Possinger K,Labianca R,Navarro M,Morant R,Bleiberg H,Wils J,Awad L,Herait P,Jacques C.Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.Lancet 1998; 352:1407-1412.
  • 7Rothenberg ML,Cox JV,DeVore RF,Hainsworth JD,Pazdur R,Rivkin SE,Macdonald JS,Geyer CE Jr,Sandbach J,Wolf DL,Mohrland JS,Elfring GL,Miller LL,Von Hoff DD.A multicenter,phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.Cancer 1999; 85:786-795.
  • 8Lu C,El-Deiry WS.Targeting p53 for enhanced radio-and chemo-sensitivity.Apoptosis 2009; 14:597-606.
  • 9Lam AK,Ong K,Ho YH.hTERT expression in colorectal adenocarcinoma:correlations with p21,p53 expressions and clinicopathological features.Int J Colorectal Dis 2008; 23:587-594.
  • 10Lam AK,Ong K,Giv MJ,Ho YH.p16 expression in colorectal adenocarcinoma:marker of aggressiveness and morphological types.Pathology 2008; 40:580-585.

共引文献60

同被引文献89

引证文献23

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部